Drug Trial Radar · NCT00364351
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jan 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,574
Actual
Start
Aug 2006
Primary completion
Sep 2008
Study completion Nov 2016
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Conditions
- Non Small Cell Lung Cancer
Interventions
VandetanibDrug
once daily oral tablet
ErlotinibDrug
oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: progressionRECIST tumour assessments carried out every 4 weeks up to week 16 then every 8 weeks thereafter from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first, assessed.
Locations
153 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Berkeley, California
Research Site
Los Angeles, California
Research Site
Santa Rosa, California
Research Site
Boynton Beach, Florida
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
Port Saint Lucie, Florida
Research Site
Wichita, Kansas
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Metairie, Louisiana
Research Site
Baltimore, Maryland
Research Site
Columbia, Missouri
Research Site
St Louis, Missouri
Research Site
Latham, New York
Research Site
Hickory, North Carolina
Research Site
Canton, Ohio
Research Site
Cincinnati, Ohio
Research Site
Greenville, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Amarillo, Texas
Research Site
Garland, Texas
Research Site
Webster, Texas
Research Site
Fairfax, Virginia
Research Site
Norfolk, Virginia
Research Site
Richmond, Virginia
Research Site
Burien, Washington
Research Site
Yakima, Washington
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Manuel B. Gonnet, Argentina
Research Site
Ramos Mejía, Argentina
Research Site
Rosario, Argentina
Research Site
Santa Fe, Argentina
Research Site
Ashford, Australia
Research Site
Bedford Park, Australia
Research Site
Chermside, Australia
Research Site
Geelong, Australia
Research Site
Hornsby, Australia
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.